Clinical Research Unit, Russell's Hall Hospital, Dudley, DY1 2HQ, U.K.
Anticancer Res. 2014 Mar;34(3):1147-51.
Breast cancer is the most common cancer in females in the UK and has greater severity in patients who overexpress human epidermal growth receptor 2 (HER2) proteins in the breast tissue. Trastuzumab is a humanised monoclonal antibody and is targeted towards blocking the HER2 pathway and effectively reduces the recurrence of breast cancer and associated mortality. However, trastuzumab is also associated with an increased risk of cardiotoxicity which likely results from inhibition of the HER2 pathway. Under normal conditions HER2 pathways help maintain the integrity of the myocardial contractile elements, as well as the coronary vasculature, but trastuzumab inhibits these survival pathways and increases the risk for congestive heart failure (CHF). In the present review, we summarise the pathways that are implicated in the development of CHF in patients receiving trastuzumab. We also highlight the role of trastuzumab-mediated endothelial dysfunction and CHF.
在英国，乳腺癌是女性中最常见的癌症，在乳房组织中过度表达人表皮生长因子受体 2 (HER2) 蛋白的患者中更为严重。曲妥珠单抗是一种人源化单克隆抗体，旨在阻断 HER2 途径，有效降低乳腺癌复发和相关死亡率。然而，曲妥珠单抗也与心脏毒性风险增加相关，这可能是由于 HER2 途径的抑制。在正常情况下，HER2 途径有助于维持心肌收缩成分和冠状动脉血管的完整性，但曲妥珠单抗抑制这些生存途径，增加充血性心力衰竭 (CHF) 的风险。在本综述中，我们总结了接受曲妥珠单抗治疗的患者发生 CHF 的相关途径。我们还强调了曲妥珠单抗介导的内皮功能障碍和 CHF 的作用。
